7 min. Read

PHTI’s premature PDT pricing analysis. CPT billing code rejects.

Issue 247

Welcome back to E&O: SaMD, a paying subscribers-only weekly newsletter focused on the world of digital pharma products, prescription digital therapeutics and other FDA-regulated digital health.

E&O: Software as a Medical Device

Here's two quick notes before we get into new CPT billing code application rejections and the latest PHTI assessment, which used some curious numbers to conclude that mental health-focused PDTs should be

Sign-up for the newsletter for access.

It's a good one, too.

This article is for Exits & Outcomes subscribers only. Subscribe now to get the weekly newsletter. Enter your email below to subscribe today!

Newsletters

Flo Health’s 2025 revenue, expenses, losses and more.

7.31.26

4 min. Read

Samsung’s ACCESS Model partner. More ACCESS dropouts. Trials.

7.24.26

6 min. Read

CMS proposes to gut RPM/RTM. Thyme revenue. Swing Therapeutics acquired.

7.15.26

6 min. Read

Clinical trials snapshot: OpenEvidence, Hinge, Oura, North Shore Therapeutics, and more

7.10.26

9 min. Read

Hello Heart, Form Health pricing. Headway off the ACCESS Model list

6.26.26

3 min. Read

Oura subscription revs, rings sold, hardware margin. New ACCESS Model participants

6.05.26

7 min. Read

Six years of Oura’s financials: Revenue, profits, marketing spend and more

5.22.26

4 min. Read

ACCESS Model’s first dropout? Plus: A few new participants

5.08.26

6 min. Read

Are these Utah’s next four AI experiments? Plus: More on the Utah Pharmacy Board’s questions about Doctronic

4.17.26

9 min. Read

Emails show how Doctronic’s AI pilot blindsided Utah’s Medical Board

4.10.26

13 min. Read

PHTI’s premature PDT pricing analysis. CPT billing code rejects.

E&O: Software as a Medical Device

Sign-up for the newsletter for access.

E&O's weekly newsletter.